PCM
MDGL icon

Prelude Capital Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Prelude Capital Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-430
Closed -$250K – 1441
2025
Q4 		$250K Buy
+430
New +$220K 0.02% 891
2024
Q3 		– Sell
-2,500
Closed -$700K – 1446
2024
Q2 		$700K Buy
2,500
+464
+23% +$110K 0.05% 398
2024
Q1 		$544K Sell
2,036
-964
-32% -$227K 0.03% 603
2023
Q4 		$694K Buy
3,000
+981
+49% +$172K 0.05% 401
2023
Q3 		$295K Buy
2,019
+678
+51% +$128K 0.02% 678
2023
Q2 		$310K Buy
+1,341
New +$363K 0.02% 629
2018
Q3 		– Sell
-25
Closed -$6.27K – 1917
2018
Q2 		$7K Buy
+25
New +$4.39K ﹤0.01% 1529

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Prelude Capital Management's MDGL Position: Q1 2026 in Review

Prelude Capital Management sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2026, closing a stake of 430 shares — an estimated $250K sold.

Prelude Capital Management first reported a position in MDGL in Q2 2018 and held it in 7 quarters. The position peaked at $700K in Q2 2024. 380 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • Prelude Capital Management reported no remaining Madrigal Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Prelude Capital Management sold 430 Madrigal Pharmaceuticals shares in Q1 2026, an estimated $250K.
  • Prelude Capital Management first reported a position in Madrigal Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Prelude Capital Management's Madrigal Pharmaceuticals position peaked at $700K in Q2 2024.
  • 380 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.